Form 4: Twist Bio CEO Sells Shares for Tax Obligations
Insider Transaction Report
Twist Bioscience CEO Emily M. Leproust sold 476 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.
Summary
- Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (TWST), reported a transaction on October 2, 2025.
- She sold 476 shares of common stock at a price of $29.161 per share.
- This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units, and was not a discretionary trade.
- Following this transaction, Leproust directly beneficially owns 632,560 shares of common stock.
- The filing also details several employee stock options with various exercise prices and vesting schedules, including 64,950 performance stock options that vested on December 19, 2022, after applicable performance criteria were met.
Sentiment
Score: 6
Explanation: The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a neutral to slightly positive event as it does not signal a lack of confidence from the insider. The insider retains a substantial equity stake.
Positives
- The sale of shares by the CEO was a mandated 'sell to cover' transaction for tax withholding, indicating it was not a discretionary trade driven by a lack of confidence in the company.
- The CEO continues to hold a significant number of shares (632,560) and various stock options, aligning her interests with shareholders.
Negatives
- No direct negatives related to company performance or operational issues are present in this Form 4 filing.
Risks
- No specific risks to the company's operations, financial health, or strategic direction are mentioned in this Form 4 filing.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' for tax purposes, which is common practice across all industries for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive positioning for Twist Bioscience.
Stakeholder Impact
- The transaction is a routine 'sell to cover' for tax purposes and is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors. It reflects standard equity compensation practices.
Next Steps
- The filing does not mention any specific future actions, events, or milestones for the company.
Key Dates
| Date | Description |
|---|---|
| 2016-09-01 | 25% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 2017-09-28 | 10% of shares subject to an employee stock option vested. |
| 2018-09-28 | 15% of shares subject to an employee stock option vested. |
| 2019-10-31 | 20% of shares subject to an employee stock option vested and became exercisable, with 1/60th vesting monthly thereafter. |
| 2020-09-01 | Grant date for performance stock options. |
| 2020-10-24 | 25% of shares subject to an employee stock option vested, with 1/48th vesting monthly thereafter. |
| 2022-12-19 | Performance stock options for 64,950 shares vested and became exercisable due to performance criteria being met. |
| 2025-09-28 | Expiration date for an employee stock option with an exercise price of $5.95. |
| 2025-10-02 | Date of common stock sale transaction by Emily M. Leproust. |
| 2025-10-06 | Signature date of the Form 4 filing. |
| 2027-09-28 | Expiration date for an employee stock option with an exercise price of $8.82. |
| 2028-11-18 | Expiration date for an employee stock option with an exercise price of $26.66. |
| 2029-10-23 | Expiration date for an employee stock option with an exercise price of $23.33. |
| 2030-08-31 | Expiration date for an employee stock option with an exercise price of $67.85. |
Keywords
Twist Bioscience, TWST, SEC Form 4, Insider Trading, Emily M. Leproust, CEO, Stock Sale, Restricted Stock Units, Equity Incentive Plan, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.